LICHTSTRASSE 35, BASEL, V8
First Quarter 2026 Condensed Interim Financial Report – Supplementary Data
Files Report on Form 6-K Dated March 18, 2026
Fourth Quarter and Full Year 2025 Condensed Financial Report – Supplementary Data
Reports on Form 6-K dated February 4, 2026
Receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Files Report on Form 6-K Dated November 5, 2025
Third Quarter and Nine Months 2025 Condensed Interim Financial Report – Supplementary Data
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Additional Information Statement
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Free Writing Prospectus
Iran Notice
S-8 POS
Amended Tender Offer Statement by Third Party